Tyra Biosciences, Inc. (TYRA)
$
29.46
-1.31 (-4.45%)
Key metrics
Financial statements
Free cash flow per share
-1.5284
Market cap
1.6 Billion
Price to sales ratio
0
Debt to equity
0.0211
Current ratio
17.7099
Income quality
0.8158
Average inventory
0
ROE
-0.3576
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Tyra Biosciences, Inc., a preclinical-stage biopharmaceutical company focused on developing therapies to combat tumor resistance and improve cancer patient outcomes, showcases strong financial performance. The gross profit stands at $0.00 highlighting the company's profitability from core operations. Such profitability is further emphasized by a gross profit ratio of 0.00 reflecting the efficiency of the company's production and sales operations. In addition to core revenues, the company earned an interest income of $17,696,000.00 showcasing its financial investments. Tyra's revenue reached $0.00 indicating its targeted focus in a niche market. The company's stock is identified with the symbol 'TYRA' in the market, allowing investors to easily track its performance. As a player in the biopharmaceutical sector, Tyra Biosciences, Inc. presents an appealing investment opportunity. The stock is affordable at $12.50 suitable for budget-conscious investors looking to enter the market. However, it has a low average trading volume of 583,365.00 indicating lower market activity, which may reflect investor interest levels. With a market capitalization of $1,572,342,007.00 the company is classified as a small-cap player, contributing to its unique position within the industry. It is a key player in the Biotechnology industry, driving innovation and growth in the biopharmaceutical landscape, and it belongs to the Healthcare sector, which emphasizes the importance of its contributions to advancing therapeutic solutions.
Is Tyra Biosciences, Inc. (TYRA) a good investment?
Investing in Tyra Biosciences, Inc. (TYRA) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as C+, with a Bearish outlook. Always conduct your own research before investing.
What is Tyra Biosciences, Inc. (TYRA)'s stock forecast?
Analysts predict Tyra Biosciences, Inc. stock to fluctuate between $6.42 (low) and $32.44 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Tyra Biosciences, Inc.'s market capitalization?
As of 2026-02-05, Tyra Biosciences, Inc.'s market cap is $1,572,342,007, based on 53,372,098 outstanding shares.
How does Tyra Biosciences, Inc. compare to competitors like Meta Platforms, Inc. Class A Common Stock?
Compared to Meta Platforms, Inc. Class A Common Stock, Tyra Biosciences, Inc. has a Lower Market-Cap, indicating a difference in performance.
How can I buy Tyra Biosciences, Inc. (TYRA) stock?
To buy Tyra Biosciences, Inc. (TYRA) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for TYRA. Place an order (Market, Limit, etc.).
What is the best time to invest in Tyra Biosciences, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
How did Tyra Biosciences, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$1.51 | Growth: -6.79%.
Where can I find Tyra Biosciences, Inc.'s investor relations reports?
Visit https://www.tyra.bio/investor-relations for detailed financial reports.
Where can I find historical stock prices for Tyra Biosciences, Inc.?
You can explore historical data from here
What is the all-time high and low for Tyra Biosciences, Inc. stock?
All-time high: $32.44 (2026-01-27) | All-time low: $4.93 (2022-06-21).
What are the key trends affecting Tyra Biosciences, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
defenseworld.net
a month ago
AquaBounty Technologies (NASDAQ: AQB - Get Free Report) and Tyra Biosciences (NASDAQ: TYRA - Get Free Report) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, dividends, institutional ownership, analyst recommendations, risk and profitability. Institutional and Insider Ownership 8.9% of AquaBounty
fool.com
a month ago
Robert More reported the sale of 246,871 shares on Nov. 21 as part of a Rule 10b5-1 trading plan. The director still owns nearly 4 million shares, worth approximately $77.6 million.
defenseworld.net
a month ago
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have been assigned an average recommendation of "Moderate Buy" from the seven analysts that are presently covering the firm, MarketBeat.com reports. One investment analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has given a strong buy
defenseworld.net
2 months ago
Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) hit a new 52-week high during trading on Friday. The stock traded as high as $24.26 and last traded at $23.9230, with a volume of 86224 shares trading hands. The stock had previously closed at $22.99. Wall Street Analyst Weigh In A number of brokerages recently
prnewswire.com
2 months ago
CARLSBAD, Calif. , Dec. 1, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today the appointment of two key members of its leadership team: Bhavesh Ashar as Chief Operating Officer and Heather Faulds as Chief Regulatory Officer.
prnewswire.com
3 months ago
CARLSBAD, Calif. , Nov. 12, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that members of company management will participate in the following investor events: Jefferies London Healthcare Conference Format: Hybrid presentation (slides & moderated Q&A) and one-on-one investor meetingsPresentation Date/Time: Wednesday, November 19, 2025, at 4:00 PM GMT Location: London, UK 37th Annual Piper Healthcare Conference Format: One-on-one investor meetingsDate: December 2-4, 2025 Location: New York, NY A live webcast of the Jefferies event can be accessed by visiting the "For Investors" page on the Tyra Biosciences website and will be available for replay following the event.
prnewswire.com
3 months ago
- Dosed first patients with dabogratinib in BEACH301 and SURF302; interim results from both studies expected in 2026 - - Expanded development of dabogratinib into low-grade upper tract urothelial carcinoma (LG-UTUC); IND cleared with U.S. FDA - - Cash, cash equivalents, and marketable securities of $274.9 million at Q3 2025; runway through at least 2027 - CARLSBAD, Calif. , Nov. 5, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, today reported financial results for the third quarter ended September 30, 2025, and highlighted recent corporate progress.
defenseworld.net
3 months ago
Shares of Tyra Biosciences, Inc. (NASDAQ: TYRA - Get Free Report) have received an average rating of "Moderate Buy" from the seven ratings firms that are currently covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell recommendation, five have issued a buy recommendation and one has issued a
prnewswire.com
6 months ago
-Dabogratinib is the only oral FGFR3-selective inhibitor in clinical development for achondroplasia- -Initial results from safety sentinel cohort expected in 2H 2026- CARLSBAD, Calif. , Aug. 21, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that the first child has been dosed in BEACH301, a Phase 2 clinical study evaluating the safety and efficacy of dabogratinib in children with achondroplasia, the most common form of dwarfism.
prnewswire.com
6 months ago
CARLSBAD, Calif. , Aug. 20, 2025 /PRNewswire/ -- Tyra Biosciences, Inc. (Nasdaq: TYRA), a clinical-stage biotechnology company focused on developing next-generation precision medicines that target large opportunities in Fibroblast Growth Factor Receptor (FGFR) biology, announced today that members of company management will participate in the following investor events: Virtual H.C.
See all news
